Sleep-related hypermotor epilepsy (SHE): Contribution of known genes in 103 patients

• Published in: Seizure (London, England) Vol. 74; pp. 60 - 64
• Main Authors: Licchetta, Laura, Pippucci, Tommaso, Baldassari, Sara, Minardi, Raffaella, Provini, Federica, Mostacci, Barbara, Plazzi, Giuseppe, Tinuper, Paolo, Bisulli, Francesca, Bianchi, Amedeo, Striano, Pasquale, Gambardella, Antonio, Giordano, Lucio, Santucci, Margherita, Meletti, Stefano, Crichiutti, Giovanni, Marini, Carla, Vignoli, Aglaia, Dilena, Roberto, Briatore, Eleonora
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2020
• Subjects: Genetics; Nocturnal frontal lobe epilepsy; Sleep-related hypermotor epilepsy; Nocturnal frontal lobe epilepsy; Sleep-related hypermotor epilepsy; Genetics
• ISSN: 1059-1311; 1532-2688
• DOI: 10.1016/j.seizure.2019.11.009

•We analyzed 103 SHE patients to estimate the mutation frequency of the known genes.•We identified mutations in CHRNA4 (2.9 %), KCNT1 (1 %), DEPDC5 (3.9 %) and NPRL2 (1 %).•The frequency of pathogenic variants was 19 % in familial and 7 % in isolated cases.•DEPDC5 shows the highest frequency, especially in cases with a structural etiology. Genetics of Sleep-related Hypermotor Epilepsy (SHE) includes mutations in several genes that cumulatively account for 30 % of families. This approximate estimate comes from different case-series, each focused on the screening of a single gene. We systematically investigated a large cohort of SHE patients to estimate the frequency of pathogenic variants in the main genes thus far implicated in this epilepsy syndrome. We selected familial and isolated cases diagnosed with clinical/confirmed SHE who underwent genetic analysis by comparable next generation sequencing (NGS) techniques (WES/ multigene epilepsy panel). The identified heterozygous variants were classified according to the American College of Medical Genetics and Genomics guidelines. We included 103 SHE patients (M/F:61/42) who underwent NGS. Sixteen (15.5 %) were familial cases, 16.5 % had focal cortical dysplasia (FCD). We identified three pathogenic variants in CHRNA4 (2.9 %, CI: 0.6–8.3 %), two of whom novel; one pathogenic variant in KCNT1 (1 %, CI: 0.02–5.29 %); four loss-of-function variants in DEPDC5 (3.9 %, CI: 1.1–9.7 %), one of whom never reported; finally, one missense change in NPRL2 (1 %, CI: 0.02–5.29 %), already reported as pathogenic. Three out of the four patients with DEPDC5 variants had FCD. The overall frequency of pathogenic variants in our SHE cohort was 8.7 %, 19 % and 7 % considering familial and sporadic cases, respectively. Pathogenic variants in the GATOR1-complex genes account for 5 % of the cases. DEPDC5 shows the highest variants frequency, especially in patients with genetic-structural etiology. From a practical perspective, analysis of this gene is recommended even in isolated cases, because of possible implications for patient management.